Bill
HR 4623
Overview: HR 4623, the Plain Prescription Prices Act, was introduced in the House on July 22, 2025.Purpose and Intent: The bill aims to increase transparency and clarity around pre
Overview: HR 4623, the Plain Prescription Prices Act, was introduced in the House on July 22, 2025.
Purpose and Intent: The bill aims to increase transparency and clarity around prescription drug pricing by requiring pharmaceutical companies to provide clear, easy-to-understand pricing information to consumers.
Key Provisions:
- Mandates that drug manufacturers display the list price, any patient assistance programs, and the net price after discounts on all prescription drug advertisements and packaging
- Requires pharmacies to provide patients with a breakdown of the total cost, including the list price, patient out-of-pocket costs, and any applicable discounts or coupons
- Directs the FDA to develop standardized labeling and disclosure requirements for prescription drug pricing information
- Establishes penalties for non-compliance, including fines and potential exclusion from federal health programs
Affected Parties and Impacts: The bill would directly benefit consumers by providing them with clear, upfront information about the true cost of their prescriptions. Pharmaceutical companies and pharmacies would be required to adapt their pricing and disclosure practices to comply with the new requirements.
Procedural and Timeline Considerations: The bill has been introduced in the House and is currently awaiting committee assignment and further legislative action.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
